ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO

Marla C. Dubinsky  1     Geert R. D'Haens  2     William Sandborn  3     Siew C. Ng  4     Julian Panés  5     Chinyu Su  6     Nervin Lawendy  6     Irina Lazariciu  7     Sean Gardiner  7     Rajiv Mundayat  7     nicole kulisek  7     Irene Modesto  7     Joana Torres  8    
1 Icahn School of Medicine at Mount Sinai, New York, United States
2 Amsterdam University Medical Centres, Amsterdam, Netherlands
3 University of California San Diego, La Jolla, United States
4 LKS Institute of Health Science, Chinese University of Hong Kong, Institute of Digestive Disease, Hong Kong, Hong Kong
5 Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
6 Pfizer Inc, Collegeville, United States
7 Pfizer Inc, New York, United States
8 Hospital Beatriz Ângelo, Loures and Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing